Core Insights - Twist Bioscience reported a strong first-quarter performance for fiscal 2026, with revenue reaching $103.7 million, reflecting a 17% year-over-year growth and marking the 12th consecutive quarter of revenue growth [5][4]. - The growth was significantly driven by demand for AI-enabled discovery, with over $25 million in orders specifically tied to this area booked for fiscal 2025 [1][5]. - The company aims for adjusted EBITDA break-even by the fourth quarter of fiscal 2026, while also increasing operating expenses to support growth [13][5]. Financial Performance - DNA synthesis and protein solutions (DSPS) revenue increased to $51.1 million, up 27% year-over-year [1]. - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million compared to the prior-year quarter [3]. - Gross margin was reported at 52.0%, higher than expected, attributed to revenue growth and process improvements [4]. Market Trends - The company is expanding its services beyond DNA synthesis to include protein expression and antibody characterization, targeting large pharma, tech companies, and well-funded biotechs [6]. - NGS applications revenue was approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [7]. - Therapeutics revenue increased to approximately $37.2 million, up 39% year-over-year, driven by greater uptake from large pharma and biotech [15]. Guidance and Outlook - Twist raised its full-year revenue outlook to $435 million to $440 million, indicating about 16% growth at the midpoint [12]. - For the second quarter, the company expects revenue of $107 million to $108 million, also reflecting about 16% growth at the midpoint [12]. - Management expressed confidence in continued growth in NGS driven by key accounts and partnerships [9][10]. Geographic and Sector Performance - Revenue by geography showed growth in the Americas ($58.4 million), EMEA ($38.4 million), and APAC ($7.0 million) compared to the previous year [11]. - Global supply partner revenue rose to $12.8 million, a 50% increase, attributed to new partnerships and growth among diagnostics OEM partners [11]. - Academic research and government revenue remained flat at approximately $12.2 million, with expectations for growth in the second quarter due to increased confidence in NIH funding [15].

Core Viewpoint - Twist Bioscience is positioned as an emerging leader in life science tools, focusing on a semiconductor approach to DNA synthesis and serving multiple applications in the multibillion-dollar markets [2][3]. Group 1: Company Overview - Twist Bioscience operates globally and is recognized for outperforming in the markets it serves [2]. - The company offers a diverse range of products, including DNA synthesis and protein solutions, as well as applications in next-generation sequencing (NGS) [3]. Group 2: Key Applications - The primary applications of Twist's technology include therapeutic drug discovery, diagnostics, and sustainable chemical production using engineered organisms [3]. - The company emphasizes its role in enhancing food security through the engineering of traits in plants and animals [3]. Group 3: Market Position - Twist Bioscience serves top-tier institutions across various markets, indicating a strong reputation and demand for its products [4].

Summary of Twist Bioscience FY Conference Call Company Overview - **Company**: Twist Bioscience (NasdaqGS:TWST) - **Industry**: Life Science Tools - **Key Technology**: Semiconductor approach to DNA synthesis - **Core Products**: DNA synthesis, protein solutions, NGS applications, and AI-driven drug discovery solutions [2][3] Market Position and Growth - **Customer Base**: Nearly 4,000 customers across various markets [3] - **Serviceable Addressable Market (SAM)**: - 2020: $2 billion - 2025: $7 billion - 2030 (projected): >$12 billion [4][5] - **Revenue Growth**: - Over 20% year-over-year growth last year - 12 consecutive quarters of revenue growth at a CAGR of 24% [5][9] Financial Performance - **Gross Margin**: Exceeded 50% last year, with a focus on revenue growth rather than gross margin growth moving forward [8][22] - **Adjusted EBITDA Break-even**: Expected in Q4 2026, marking a significant milestone for the company [6][22] - **Q1 FY 2025 Performance**: - DNA synthesis and protein solutions revenue: $52 million (27% growth) - NGS application revenue: $53 million (8% growth, 18% excluding one transitioning customer) [23][24] Product and Innovation Strategy - **NPI (New Product Introduction) Machine**: Continuous product development leading to a diverse product lineup, enhancing competitive advantage [4][19] - **AI Drug Discovery**: Contributed $25 million to revenue growth in FY 2025, with a focus on large pharma, AI companies, and the "Magnificent Seven" tech firms [12][28] - **Customer Engagement**: Strategy to expand wallet share by upselling additional products and services to existing customers [11][12] Competitive Advantages - **Product Quality and Speed**: Ability to deliver high-quality products quickly and at competitive prices, which is a key factor for customer retention and acquisition [11][26] - **Operational Excellence**: Leveraging automation to maintain low variable costs and high gross margins [21][22] - **Market Adaptability**: Ability to pivot and meet customer needs, especially in the rapidly evolving AI drug discovery space [13][27] Industry Dynamics - **NGS Applications**: Majority of revenue derived from diagnostic companies, with a strong correlation between diagnostic revenue growth and Twist's revenue [31] - **Impact of Sequencing Costs**: Lower sequencing costs are expected to benefit the business by making tests more affordable and accessible [40][41] Future Outlook - **Growth Strategy**: Focus on continuous product launches, expanding SAM, and maintaining high customer satisfaction [44] - **Market Positioning**: Despite strong performance, the company believes its market valuation does not reflect its execution and innovation compared to competitors [44] Conclusion - Twist Bioscience is positioned for significant growth with a robust product pipeline, strong financial performance, and a strategic focus on innovation and customer satisfaction. The company aims to leverage its technological advantages to capture a larger share of the expanding life science tools market [22][44]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [7] - For the full fiscal year 2025, revenue reached $376.6 million, a growth of 20% compared to fiscal 2024 [7][23] - Gross margin for Q4 was 51.3%, and for the full year, it was 50.7%, an increase from 42.6% in fiscal 2024 [7][23] Business Line Data and Key Metrics Changes - Synbio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million from $123.5 million in fiscal 2024 [8][23] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, with full-year revenue at $208.1 million, reflecting a 23% growth [12][24] - Biopharma revenue for Q4 was $6.4 million, a 22% increase year-over-year, with full-year revenue at $23.5 million, a 15% growth [14][24] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [25] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth [25] Company Strategy and Development Direction - The company plans to combine Synbio and Biopharma revenue reporting under the term "DNA synthesis and protein solutions" to better reflect its customer base [16] - A focus on AI-driven drug discovery is expected to drive future growth, with significant orders from customers in this area [10][29] - The introduction of the MRD Express product is aimed at enhancing cancer diagnostics and treatment, with a commercial launch expected in early 2026 [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth opportunities, particularly in AI-enabled drug discovery and the integration of Synbio and Biopharma services [10][32] - The company anticipates total revenues for fiscal 2026 to be between $425 million and $435 million, reflecting a growth of approximately 13% to 15.5% year-over-year [29] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [28] - Adjusted EBITDA for Q4 was a loss of approximately $7.8 million, an improvement of $9.2 million compared to Q4 of fiscal 2024 [27] Q&A Session Summary Question: On gross margins and pricing - Management indicated that while they expect to maintain strong gross margins, specific customer mix may influence quarterly results [36][37] Question: NGS growth expectations - Management expects NGS growth to return to 20% by Q4, driven by customer transitions and new product introductions [38] Question: Sustainability of AI-driven biopharma orders - Management remains optimistic about the biopharma business, highlighting the close ties to Synbio offerings and the potential of AI [40][41] Question: Guidance for gross margins and NGS portfolio - Management anticipates improvements in gross margins throughout the year, driven by revenue growth and continuous process improvements [43][44] Question: Market opportunity definition - Management acknowledged the need for clearer market definitions and metrics to help investors understand growth potential [59][62]